文献速递浆细胞疾病造血干细胞移植与细胞治疗

BCMAxCD3双特异性抗体与抗BCMA CAR T细胞抗肿瘤疗效相似

A BCMAxCD3 bispecific T cell-engaging antibody demonstrates robust antitumor efficacy similar to that of anti-BCMA CAR T cells.
PubMed 文献 · Blood Adv · 2021-01-01

研究描述全人源BCMAxCD3双特异性抗体REGN5458,并在体外和体内比较其与抗BCMA CAR T细胞的抗肿瘤活性。体外两者对MM细胞系和原代MM细胞杀伤相似,体内bsAb清除已建立系统性MM肿瘤更快,而CAR T细胞动力学较慢。

要点

  • BCMAxCD3 bsAb体外高效诱导多克隆T细胞杀伤原代浆细胞和MM细胞系。
  • 体内bsAb快速清除已建立系统性MM肿瘤,CAR T细胞清除动力学较慢。
  • bsAb与PD-1阻断联合显示强效协同疗效。

核心结论

  • 使用相同BCMA结合域时,BCMAxCD3 bsAb与抗BCMA CAR T细胞体外靶向细胞毒性相似,但体内bsAb起效更快。

研究设计与样本

  • 研究描述全人源BCMAxCD3双特异性抗体REGN5458,并在体外及小鼠异种移植模型中与抗BCMA CAR T细胞进行头对头比较。

主要发现

  • 体外BCMAxCD3 bsAb高效诱导多克隆T细胞杀伤原代人类浆细胞及表达不同BCMA表面密度的多发性骨髓瘤细胞系。
  • 体内BCMAxCD3 bsAb抑制人MM肿瘤生长,并与PD-1阻断联合显示强效协同疗效。
  • 食蟹猴给药耐受良好,导致BCMA+细胞耗竭及以CRP和血清细胞因子短暂升高为特征的轻度炎症反应。
  • 体外BCMAxCD3 bsAb与抗BCMA CAR T细胞对MM细胞系和原代MM细胞显示相似的靶向细胞毒性。
  • 头对头体内研究中,BCMAxCD3 bsAb快速清除已建立系统性MM肿瘤,而CAR T细胞清除肿瘤动力学较慢。

临床怎么用

  • BCMAxCD3 bsAb可能通过招募肿瘤部位已存在的T细胞快速起效,而CAR T细胞需时间转运、激活和扩增。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CD3-engaging bispecific antibodies (bsAbs) and chimeric antigen receptor (CAR) T cells are potent therapeutic approaches for redirecting patient T cells to recognize and kill tumors. Here we describe a fully human bsAb (REGN5458) that binds to B-cell maturation antigen (BCMA) and CD3, and compare its antitumor activities vs those of anti-BCMA CAR T cells to identify differences in efficacy and mechanism of action. In vitro, BCMAxCD3 bsAb efficiently induced polyclonal T-cell killing of primary human plasma cells and multiple myeloma (MM) cell lines expressing a range of BCMA cell surface densities. In vivo, BCMAxCD3 bsAb suppressed the growth of human MM tumors in murine xenogeneic models and showed potent combinatorial efficacy with programmed cell death protein 1 blockade. BCMAxCD3 bsAb administration to cynomolgus monkeys was well tolerated, resulting in the depletion of BCMA+ cells and mild inflammatory responses characterized by transient increases in C-reactive protein and serum cytokines. The antitumor efficacy of BCMAxCD3 bsAb was compared with BCMA-specific CAR T cells containing a BCMA-binding single-chain variable fragment derived from REGN5458. Both BCMAxCD3 bsAb and anti-BCMA CAR T cells showed similar targeted cytotoxicity of MM cell lines and primary MM cells in vitro. In head-to-head in vivo studies, BCMAxCD3 bsAb rapidly cleared established systemic MM tumors, whereas CAR T cells cleared tumors with slower kinetics. Thus, using the same BCMA-binding domain, these results suggest that BCMAxCD3 bsAb rapidly exerts its therapeutic effects by engaging T cells already in place at the tumor site, whereas anti-BCMA CAR T cells require time to traffic to the tumor site, activate, and numerically expand before exerting antitumor effects.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. DiLillo DJ, Olson K, Mohrs K, et al. A BCMAxCD3 bispecific T cell-engaging antibody demonstrates robust antitumor efficacy similar to that of anti-BCMA CAR T cells. Blood Adv. 2021. PMID: 33651100. doi:10.1182/bloodadvances.2020002736

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。